

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 16758

Title: Novel therapeutic approaches for hepatitis B virus cccDNA

Reviewer's code: 02439938

Reviewer's country: China

Science editor: Yuan Qi

Date sent for review: 2015-01-29 21:44

Date reviewed: 2015-02-05 01:21

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

Comments to the authors: Title: "Novel therapeutic approaches for hepatitis B virus cccDNA" This manuscript provides a review on the advance and potential application for HBV treatment. This is a good article and help readers to understand new methods to cure HBV infection. But it will be better for readers to understand if authors can have a picture, which illuminates how the CRISPR/Cas9 system work on HBV cccDNA. And also there are some spellings mistakes within manuscript and need to be revised, such as "INF", it should be "IFN".

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 16758

Title: Novel therapeutic approaches for hepatitis B virus cccDNA

Reviewer's code: 02841615

Reviewer's country: China

Science editor: Yuan Qi

Date sent for review: 2015-01-29 21:44

Date reviewed: 2015-03-06 18:11

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This manuscript reviewed a novel therapeutic approaches for hepatitis B virus cccDNA related with the CRISPR/Cas9 system. It is an easily customizable sequence-specific nuclease with great flexibility and may be the most feasible approach to target HBV cccDNA, which is valuable to do further research into more effective protocols.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 16758

Title: Novel therapeutic approaches for hepatitis B virus cccDNA

Reviewer's code: 03020625

Reviewer's country: China

Science editor: Yuan Qi

Date sent for review: 2015-01-29 21:44

Date reviewed: 2015-03-20 23:04

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> [Y] Accept
<input type="checkbox"/> [Y] Grade B: Very good	<input type="checkbox"/> [Y] Grade B: Minor language polishing	<input type="checkbox"/> [] The same title	<input type="checkbox"/> [] High priority for publication
<input type="checkbox"/> [] Grade C: Good	<input type="checkbox"/> [] Grade C: A great deal of language polishing	<input type="checkbox"/> [] Duplicate publication	<input type="checkbox"/> [] Rejection
<input type="checkbox"/> [] Grade D: Fair	<input type="checkbox"/> [] Grade D: Rejected	<input type="checkbox"/> [Y] No	<input type="checkbox"/> [] Minor revision
<input type="checkbox"/> [] Grade E: Poor		BPG Search:	<input type="checkbox"/> [] Major revision
		<input type="checkbox"/> [] The same title	
		<input type="checkbox"/> [] Duplicate publication	
		<input type="checkbox"/> [] Plagiarism	
		<input type="checkbox"/> [Y] No	

COMMENTS TO AUTHORS

In this review, the authors reviewed the novel therapeutic approaches for HBV cccDNA, which is favorable for the clinician in various fields. As one of the genome-editing methods, CRISPR/Cas9 system has triggered a revolution in which laboratories around the world are using the technology for innovative applications in biology. Being a potential therapeutic approach, it would be better to list some HBV-specific gRNA in this article. The paper could be accepted by minor revision, such as "INF".